- 2.1.1 2023 Update to guideline
- 2.1.2 Summary of trial evidence on kidney disease progression
- 2.1.3 Summary of trial evidence on cardiovascular risk
- 2.1.4 Benefits and risks of SGLT-2 inhibition in people with type 2 DM
- 2.1.5 Summary of trial evidence on glucose-lowering effects
- 2.1.6 Quality of the evidence
- 2.1.7 Summary of published cost-effectiveness analyses
Navigate to sections